Ontology highlight
ABSTRACT:
SUBMITTER: Liang X
PROVIDER: S-EPMC6736652 | biostudies-literature | 2019 Aug
REPOSITORIES: biostudies-literature
Liang Xu X Li Huiping H Coussy Florence F Callens Celine C Lerebours Florence F
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 20190801 4
As the first monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab (BEV) is a definitely controversial antiangiogenic therapy in breast cancer. The initial excitement over improvements in progression-free survival (PFS) with BEV was tempered by an absence of overall survival (OS) benefit and serious adverse effects. Missing targeted population urged us to identify the predictive biomarkers for BEV efficacy. In this review we focus on the research in breast cancer and ...[more]